Novartis Ag (NVS) Retained Earnings (2009 - 2025)

Novartis Ag's Retained Earnings history runs 11 years deep, the most recent figure standing at $45.4 billion for Q4 2025.

• In Q4 2025, Retained Earnings rose 4.87% year-over-year to $45.4 billion; the TTM figure through Dec 2025 stood at $45.4 billion (up 4.87% YoY), while the FY2025 annual figure was $45.4 billion, up 4.87% from the prior year.
• Retained Earnings came in at $45.4 billion for Q4 2025 at Novartis Ag, up from $41.3 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $66.8 billion in Q4 2021 to a low of $41.0 billion in Q2 2024.
• A 5-year average of $50.9 billion and a median of $48.5 billion in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings grew 19.85% in 2021 and retreated 21.63% in 2023, its largest moves.
• Novartis Ag's Retained Earnings stood at $66.8 billion in 2021, then declined by 12.36% to $58.5 billion in 2022, then declined by 21.63% to $45.9 billion in 2023, then declined by 5.62% to $43.3 billion in 2024, then increased by 4.87% to $45.4 billion in 2025.
• According to Business Quant data, Retained Earnings over the past three periods registered $45.4 billion, $41.3 billion, and $43.3 billion for Q4 2025, Q2 2025, and Q4 2024 respectively.

Peer Comparison